

A2 <sup>alc</sup> C2  
64. (New) The antibody of claim 61, wherein said antigen binding fragment comprises an Fv portion of an antibody.

REMARKS


Newly added claims 56-64 merely expand upon claims 21-24 as originally filed, and find support in those claims as well as throughout the specification, *e.g.*, page 21, line 22 through page 25, line 24.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version With Markings to Show Changes Made.**"

All of the claims remaining in the application are now clearly allowable. Favorable consideration and a Notice of Allowance are earnestly solicited.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



William T. Christiansen, Ph.D.

Registration No. 44,614

WTC:rap

Enclosure:

Postcard

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Abstract:

On page 56, please delete the title of the application from the abstract.

In the Specification:

On page 1 please replace the paragraph in the section entitled CROSS REFERENCE TO RELATED APPLICATIONS with the following:

This application is a divisional of U.S. Application No. 09/187,789, filed November 6, 1998; which application is a continuation-in-part of U.S. Application No. 09/139,600, filed August 25, 1998; which application claims the benefit of priority from U.S. Provisional Application No. 60/056,896, now abandoned.

In the Claims:

Please cancel claims 1-55.

Please add the following claims:

56. (New) An isolated antibody or an antigen binding fragment thereof specific for a caspase-14 polypeptide, wherein said polypeptide comprises a polypeptide sequence having greater than 80% identity with SEQ ID NO:2.

57. (New) The antibody of claim 56, wherein said antibody is a polyclonal antibody.

58. (New) The antibody of claim 56, wherein said antibody is a monoclonal antibody.

59. (New) The antibody of claim 56, wherein said antigen binding fragment comprises an Fv portion of an antibody.

60. (New) An isolated cell expressing the antibody of claim 56.

61. (New) An isolated antibody or an antigen binding fragment thereof specific for a caspase-14 polypeptide, wherein said polypeptide comprises a polypeptide sequence having greater than 80% identity with SEQ ID NO:5.

62. (New) The antibody of claim 61, wherein said antibody is a polyclonal antibody.

63. (New) The antibody of claim 61, wherein said antibody is a monoclonal antibody.

64. (New) The antibody of claim 61, wherein said antigen binding fragment comprises an Fv portion of an antibody.

273032\_1